Inhibitors & Mechanism of Action

Last Updated: 06/26/17

Tumor Inhibitors Possibilities

Inhibitors & Other Mechanisms

  1. VEGF and Angiogenic Inhibitors
  2. TKI Inhibitors
  3. HDAC Inhibition
  4. mTOR Inhibitor
  5. Anti-Inflammatory Agents
  6. PTK Inhibitors
  7. EGFR Inhibitors
  8. PI3K Inhibitor
  9. RNR Inhibitors (Discontinued)
  10. HSP90 Inhibition
  11. SOX 10 (MLN4924)

    - DT - Drug-Based Treatment
    - OTC - Over-The-Counter
    Medication or Supplement
    - F - Food
  1. VEGF and Angiogenic Inhibitors
  2. TKI Inhibitors
    1. (DT) Axitinib (Inlyta™)
    2. (DT) Lapatinib (Tykerb™)
    3. (DT) Erlotinib (Tarceva™)
    4. (DT) Sunitinib - SU011248 (Sutent™)
    5. (DT) Imatinibn, Imatinibn Mesilate
    6. (DT) Sorafenib (Nexavar™)
    7. (DT) Nilotinib (Tasigna™)
    8. (DT) Vandetanib (Zactimia™)
    9. (DT) Dasatinib (Sprycel™)
    10. (DT) Nintedanib - Intedanib - BIBF 1120
  3. HDAC Inhibition
  4. mTOR Inhibitor
  5. Anti-Inflammatory Agents
    • (OTC) Ashwagandha
    • (OTC) Berberine
    • (OTC) Boswellia (Indian Frankincense)
    • (OTC) Feverfew
      (Flower: Tanacetum parthenium)
    • (OTC) NSAID - Aspirin, Ibuprofen &
      Naproxen
      (Non-steroidal Anti-inflammatory Drugs)
    • (OTC) Yograj/Kanchnar Guggul
  6. PTK Inhibitors
    • (OTC) Apigenin
    • (OTC) Genistein
    • (OTC) Luteolin
  7. EGFR Inhibitors
  8. PI3K Inhibitor
    • (DT) BEZ235
  9. RNR Inhibitors (Discontinued)
    • (DT) Hydroxyurea (Hydrea™ and Droxia™)
  10. HSP90 Inhibition

Tumor Suppressor Possibilities

People with NF2 lack a tumor suppressor gene, which results in a damage to the MERLIN (Moesin-Ezrin-Radixin-Like) Protein. As a result tumors grow because a lack of M.E.R.L.I.N. causes cellular confusion on multiplication of different types of unnecessary cells. MERLIN is a protein that is meant to prevent the growth of tumors.

These Inhibitors will make up for the lack of Merlin and are being chosen based on their Mechanism of Action.

Medications are currently in various stages of trials for tumor suppression. Some are in mice trials while others are in various stages of human trials.

Inhibitors and Other Mechanisms

1. VEGF and Angiogenic Inhibitors

Vascular Endothelial Growth Factor Inhibition (VEGF)and Angiogenic Inhibitors, inhibit the growth of new blood vessels. While this can be done naturally by the body, it can also be done with medication or diet.

2. TKI Inhibitor

Tyrosine-Kinase Inhibitor (TKI Inhibitor). The function of TKI is to prevent the unregulated growth of a cell, by affecting cell transformation, therefore, altering cellular growth or reproduction.

3. HDAC Inhibition

Histone deacetylase inhibitors (HDACi)

4. mTOR Inhibitor

Mammalian Target of Rapamycin Inhibitor (mTOR Inhibitor) is the target of Rapamycin, aka the FK506 binding protein 12-rapamycin associated protein 1 (FRAP1), the phosphatidylinositol 3-kinase-related kinase protein family. Also known as; SKS; FRAP; FRAP1; FRAP2; RAFT1; RAPT1

5. Anti-Inflammatory Agents

Anti-inflammatories are substances, or treatments, that reduce inflammation.

6. PTK Inhibitor

Protein-Tyrosine Kinase Inhibitor, these tyrosine kinases are a form of enzyme inhibitor that regulates the cellular pathways.

7. EGFR Inhibitors

Epidermal Growth Factor Receptor (EGFR)

8. PI3K Inhibitor

Phosphoinositide 3-kinase inhibitor (PI3K)

9. RNR Inhibitors

Ribonucleotide Reductase, also known as Ribonucleoside Diphosphate Reductase(RNR). Due to long term potential complications, the RNR Inhibitors have been discontinued for use as an NF2 tumor suppressor treatment.

10. HSP90 Inhibition

None available at this time.

What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017